VTGN (Vistagen Therapeutics) FCF Margin % : 67,666.67% (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Vistagen Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vistagen Therapeutics's Free Cash Flow for the three months ended in Mar. 2025 was $-10.15 Mil. Vistagen Therapeutics's Revenue for the three months ended in Mar. 2025 was $-0.02 Mil. Therefore, Vistagen Therapeutics's FCF Margin % for the quarter that ended in Mar. 2025 was 67,666.67%.

As of today, Vistagen Therapeutics's current FCF Yield % is -60.94%.

The historical rank and industry rank for Vistagen Therapeutics's FCF Margin % or its related term are showing as below:

VTGN' s FCF Margin % Range Over the Past 10 Years
Min: -8701.23 Med: -1782.36 Max: 21994.71
Current: -8701.23

During the past 13 years, the highest FCF Margin % of Vistagen Therapeutics was 21994.71%. The lowest was -8701.23%. And the median was -1782.36%.

VTGN's FCF Margin % is ranked worse than
92.19% of 999 companies
in the Biotechnology industry
Industry Median: -102.29 vs VTGN: -8701.23

Vistagen Therapeutics FCF Margin % Historical Data

The historical data trend for Vistagen Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vistagen Therapeutics FCF Margin % Chart

Vistagen Therapeutics Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

FCF Margin %

Get a 7-Day Free Trial

-1,132.94

-4,098.92

21,994.71

-2,431.77

-8,701.23

Vistagen Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															-3,545.69	-12,989.29	-5,981.97	-4,393.16	67,666.67

Competitive Comparison of Vistagen Therapeutics's FCF Margin %

For the Biotechnology subindustry, Vistagen Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistagen Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Vistagen Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vistagen Therapeutics's FCF Margin for the fiscal year that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2025 )	/	Revenue (A: Mar. 2025 )
	=	-42.288	/	0.486
	=	-8,701.23 %

Vistagen Therapeutics's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-10.15	/	-0.015
	=	67,666.67 %

Vistagen Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vistagen Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vistagen Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vistagen Therapeutics Inc (NAS:VTGN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.vistagen.com

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Executives

Joshua S. Prince	officer: Chief Operating Officer	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Cynthia Lynn Anderson	officer: CHIEF FINANCIAL OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Jerry B Gin	director	343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Reid G. Adler	officer: CHIEF LEGAL OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94090
Shawn Singh	director, officer: CHIEF EXECUTIVE OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Eg, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Bong Y Koh	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Co-investment Holdings Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Nimish P Shah	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036